Cipher Pharmaceuticals Inc.

Toronto Stock Exchange:CPH.TO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💄 Cosmetics

💊 Drugstores & Retail Pharmacies

Location

Canada

Market Cap

USD 240.95 M

Share Price

USD 9.40

Avg Daily Volume

29,123

Change (1 day)

1.27%

Change (1 year)

51.93%

Change (YTD)

-5.50%

Cipher Pharmaceuticals Inc. Total Liabilities for the year ending December 31, 2024: USD 60.17 M

Cipher Pharmaceuticals Inc. Total Liabilities is USD 60.17 M for the year ending December 31, 2024, a 991.80% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Cipher Pharmaceuticals Inc. Total Liabilities for the year ending December 31, 2023 was USD 5.51 M, a -43.16% change year over year.
Cipher Pharmaceuticals Inc. Total Liabilities for the year ending December 31, 2022 was USD 9.70 M, a -23.98% change year over year.
Cipher Pharmaceuticals Inc. Total Liabilities for the year ending December 31, 2021 was USD 12.75 M, a 9.63% change year over year.
Cipher Pharmaceuticals Inc. Total Liabilities for the year ending December 31, 2020 was USD 11.63 M, a -36.92% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

Toronto Stock Exchange: CPH.TO

Cipher Pharmaceuticals Inc.

CEO	Mr. Craig J. Mull
IPO Date	May 7, 2004
Location	Canada
Headquarters	209 Oak Park Boulevard
Employees	5
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💄 Cosmetics 💊 Drugstores & Retail Pharmacies

Description

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.